ReviewF1000Research2019
Bronchiectasis insanity: Doing the same thing over and over again and expecting different results?
Review in F1000Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Mucoactive agents in bronchiectasis: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Adjudication of exacerbations in bronchiectasis using modified EMBARC criteria in the CLEAR Trial.ERJ open research · 2026Article
- Benralizumab in bronchiectasis: results from the phase 3 MAHALE study.ERJ open research · 2026Article
- Association of German Bronchiectasis Registry participation with disease course.ERJ open research · 2026Article
- Considerations in the Diagnosis and Management of Bronchiectasis in Older Adults.Clinics in geriatric medicine · 2025Review
- Beyond ORBIT: Mapping the Constellation of Pseudomonas Endotypes in Bronchiectasis Clinical Trials.American journal of respiratory and critical care medicine · 2025Article
- Neutrophils secrete exosome-associated DNA to resolve sterile acute inflammation.Nature cell biology · 2025Article
- The Chronic Obstructive Pulmonary Disease (COPD)-Bronchiectasis Overlap Syndrome: Does My COPD Patient Have Bronchiectasis on Computed Tomography? "Frankly, My Dear, I Don't Give a Damn!"American journal of respiratory and critical care medicine · 2023Article
- Bronchial gene expression alterations associated with radiological bronchiectasis.The European respiratory journal · 2023Article
- Evaluation of outcome reporting in clinical trials of physiotherapy in bronchiectasis: The first stage of core outcome set development.PloS one · 2023Article
- Precision medicine in bronchiectasis.Breathe (Sheffield, England) · 2021Review
- Evaluating the Prevalence and Incidence of Bronchiectasis and Nontuberculous Mycobacteria in South Korea Using the Nationwide Population Data.International journal of environmental research and public health · 2021Article
- Measuring airway clearance outcomes in bronchiectasis: a review.European respiratory review : an official journal of the European Respiratory Society · 2020Review
- Bronchiectasis and cough: An old relationship in need of renewed attention.Pulmonary pharmacology & therapeutics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bronchiectasis is an increasingly common disease with a significant impact on quality of life and morbidity of affected patients. It is also a very heterogeneous disease with numerous different underlying etiologies and presentations. Most treatments for bronchiectasis are based on low-quality evidence; consequently, no treatments have been approved by the US Food and Drug Administration or the European Medicines Agency for the treatment of bronchiectasis. The last several years have seen numerous clinical trials in which the investigational agent, thought to hold great promise, did not demonstrate a clinically or statistically significant benefit. This commentary will review the likely reasons for these disappointing results and a potential approach that may have a greater likelihood of defining evidence-based treatment for bronchiectasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.